SIRT7 and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, SIRT7 level may serve as a biomarker to monitor treatment response in acute myeloid leukemia (AML) or chronic myelogenous leukemia (CML) patients, as it is restored to normal level upon a positive treatment response but is reduced during disease relapse (30).